The U.S. Food and Drug Administration issued a warning to healthcare providers against administering the malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.
The European health regulator is looking to fast-track approval of Gilead’s antiviral remdesivir as a potential COVID-19 treatment in Europe.
Gilead Sciences Inc is developing easier-to-administer versions of the company’s antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals.
Gilead Sciences Inc.’s antiviral drug remdesivir had mixed results in a late-stage study of people with moderate COVID-19.
Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.
The U.S. National Institutes of Health (NIH) said data from the company’s trial of Gilead Sciences Inc.’s remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.
According to the World Health Organization and ClinicalTrials.gov, there are 1,114 ongoing clinical studies of treatments for COVID-19. A GlobalData analysis indicates that 21 of the trials have reported interim results, with 16 showing positive early results.
Gilead Sciences entered into licensing agreements with five generic drugmakers to make the antiviral drug Veklury (remdesivir), the first medicine shown to be effective against COVID-19, available in 127 countries.
Japan approved Gilead Sciences Inc.’s remdesivir as a treatment for COVID-19, marking the country’s first officially authorized drug to tackle the coronavirus disease.
Gilead Sciences issued a statement describing the company’s efforts of scaling up manufacturing and distribution of the antiviral drug remdesivir as a treatment for COVID-19.
